Robert Browne This is Me

Education

 Web References

1. 1. PRESS RELEASE

   netbox.pcshs.com/news/releases - [Cached]

   Published on: 1/18/1996   Last Visited: 9/4/2000

   The formulary is a valuable reference that provides clinical information about drugs, therapeutic approaches to disease states and comparative cost information, said Robert Browne, MD, vice president and chief scientific officer at PCS. The formulary helps physicians achieve the best clinical outcomes for patients while controlling costs..
   
   In one important change, PCS issued the Performance Drug List (PDL), a subset of cost-effective drugs from the PCS Clinical Formulary, as a companion piece. The Performance Drug List is a clinically approved and economically modeled list of drugs in 20 therapeutic categories. The therapeutic categories on the PDL were selected because they represent nearly 70 percent of the prescription costs of the average PCS customer.

2. 2. PRESS RELEASE

   www.pcshs.com/news/releases/19 - [Cached]

   Published on: 1/18/1996   Last Visited: 9/11/2000

   The formulary is a valuable reference that provides clinical information about drugs, therapeutic approaches to disease states and comparative cost information, said Robert Browne, MD, vice president and chief scientific officer at PCS. The formulary helps physicians achieve the best clinical outcomes for patients while controlling costs..
   
   In one important change, PCS issued the Performance Drug List (PDL), a subset of cost-effective drugs from the PCS Clinical Formulary, as a companion piece. The Performance Drug List is a clinically approved and economically modeled list of drugs in 20 therapeutic categories. The therapeutic categories on the PDL were selected because they represent nearly 70 percent of the prescription costs of the average PCS customer.